OrganiGram’s CEO Is Leaving: Newsworthy or Noise?

With the departure of OrganiGram’s (TSX:OGI)(NYSE:OGI) CEO, investors may wonder if they need to pay attention.

| More on:
calculate and analyze stock

Image source: Getty Images

OrganiGram (TSX:OGI)(NASDAQ:OGI) has been a favourite pick of investors who have been watching cannabis stocks. Recently, OrganiGram has been in the purview of investors primarily for good reasons. The company’s surging stock price and ability to capitalize on value-added products has provided mostly positive stories over the past year.

However, of late, OrganiGram has been in the news. This time, the buzz is around CEO Greg Engel, “stepping away” from his designation in OrganiGram.

Indeed, the news has stirred some investors, as the stock plummeted by 5% following the news. However, I don’t think it is going to be that big of the deal moving ahead.

Here’s why I think Greg Engel’s departure is not necessarily newsworthy and why the noise surrounding it could disappear soon.

The ties are not entirely severed

After a four-and-a-half year tenure, the CEO of OrganiGram has decided to part ways from the company and its managerial responsibilities.

However, that does not bring an end to Greg’s role in OrganiGram. As per OrganiGram, he is going to continue as a valued member of its advisory board.

Of course, his innovative leadership and proficiency have helped OrganiGram scale to new heights in the marketplace. Accordingly, some investors have been wary of the change.

That said, the past few years have shown a pattern with organizational changes. Various high-profile CEOs have stepped down or been let go. It appears to be part of the maturing process of this sector.

Accordingly, I think OrganiGram’s operations will remain undeterred from this singular event. The company’s been headed on the right track and has made a series of moves I view as positive for the cannabis player’s long-term growth objectives.

OrganiGram’s growth-by-acquisition strategy

Organigram has been making deals of late that position the company well for long-term growth.

A high-profile deal with British American Tobacco (NYSE:BTI) has sparked interest in this relatively small-cap cannabis player. Indeed, if OrganiGram can integrate its operations and business model with that of BTI, the company’s growth trajectory could change substantially for the better.

Additionally, its recent acquisition of The Edibles & Infusions Corporation deserves consideration. I think edibles is a key growth area that’s relatively under the radar right now. If OrganiGram can become a leader in this space, long-term profit margins could improve substantially.

Additionally, I like the way this deal is structured. The deal has various milestone considerations. Upon the achievement of specific targets, consideration will be paid over time, providing company investors with assurances the company didn’t overpay for this deal. I like that.

Bottom line

OrganiGram is a relatively small cannabis player in the Canadian market, with a market cap of less than $1 billion.

That said, this company is one of the best positioned for growth in terms of its recent acquisitions and strategic shifts.

Accordingly, for those looking to put a few dollars on this sector, OrganiGram is an intriguing choice. It’s not a company I’d bet the farm on, but its growth prospects do look enticing from here.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends OrganiGram Holdings. The Motley Fool recommends OrganiGram Holdings.

More on Cannabis Stocks

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »

Marijuana plant and cannabis oil bottles isolated
Energy Stocks

3 Canadian Value Stocks to Buy Right Now

Undervalued Canadian stocks such as Secure Energy should be part of your shopping list in May 2024.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Here’s Why it’s Not Too Late to Buy Cronos Group Stock

The optimism about U.S. federal marijuana legalization and its anticipation are potent bullish triggers for the Canadian cannabis industry.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Canopy Growth Stock Is on a Tear: Is it a Good Buy Now? 

Canopy Growth (TSX:WEED) stock surged by 80% from news out of the U.S., but is enough there without the news…

Read more »

Marijuana plant and cannabis oil bottles isolated
Cannabis Stocks

Prediction: These Could Be the Best-Performing Cannabis Stocks Through 2030

Quality cannabis stocks such as Green Thumb and Cresco Labs are positioned to deliver outsized gains to shareholders in 2024…

Read more »